The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2017 | ASH 2017 top picks: Phase III trials, antibody-drug conjugates and CAR T-cells
The American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, presented cutting-edge updates in hematology. Discover the top picks of this year’s meeting with Keith Stewart, MD, ChB, of the Mayo Clinic, Scottsdale, AZ. Dr Stewart highlights Phase III trials, antibody-drug conjugates and CAR T-cells, emphasizing key data showing the promise of particular therapies. He also discusses where he forsees CAR T-cell therapy moving in the next year.
